* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Pritor® 40(80) mg and Co-Pritor® 40(80/12.5 mg)
Survey
Document related concepts
Pharmaceutical industry wikipedia , lookup
Tablet (pharmacy) wikipedia , lookup
Psychopharmacology wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Transcript
Pritor® 40(80) mg and Co-Pritor® 40(80/12.5 mg) Approved indication Telmisartan (Pritor® 40(80) mg) and telmisartan/hydrochlorothiazide (Co-Pritor® 40(80)/12.5 mg) tablets are indicated for the treatment of mild to moderate hypertension. Pritor® and Co-Pritor® tablets are identical to the original products, Micardis® and CoMicardis®, are manufactured at the same factory and provide patients with an additional and more affordable presentation pack. biliary obstructive disorders or severe hepatic insufficiency. Use telmisartan cautiously in patients who have previously experienced angioedema with an ACE inhibitor. Hydrochlorothiazide is contraindicated in patients allergic to sulphonamides. Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should first be corrected before starting therapy. Mode of action Pregnancy and lactation Abnormalities in the renin-angiotensin system (RAS) play a critical role in the pathogenesis and maintenance of hypertension. Telmisartan is an angiotensin ll receptor antagonist/blocker (ARB). It displays potent and selective affinity for the AT1 receptor, thereby directly blocking angiotensin ll-induced arteriolar vasoconstriction. Hydrochlorothiazide is a low-ceiling diuretic recommended as firstline therapy in uncomplicated hypertension. Like the ACE inhibitors and other angiotensin ll receptor antagonists, telmisartan is contraindicated during pregnancy. Since there is no information available on the use of telmisartan during lactation, telmisartan is contraindicated for use during lactation. Telmisartan may be used alone or in combination with hydrochlorothiazide if further blood pressure reductions are required. Dosage Adults: 40 mg telmisartan once daily, which may be increased after 4 to 8 weeks to a maximum of 80 mg once daily. Alternatively, hydrochlorothiazide 12.5 mg once daily may be added. No dosage adjustment is required in elderly patients. Evidence of efficacy Published data on the use of telmisartan in humans confirms its sustained 24-hour antihypertensive effects and clinical efficacy. The BP-lowering efficacy over the entire 24-hour dose administration interval is consistent with the pharmacokinetic profile of telmisartan, which has the longest elimination half-life among currently available ARBs. Several controlled studies have demonstrated that the fixeddose combination of telmisartan/hydrochlorothiazide is superior in lowering blood pressure than either telmisartan or hydrochlorothiazide alone. Recent data show that telmisartan 80 mg controls the early morning blood pressure surge more effectively than ramipril 5–10 mg and, thus, may have a greater beneficial effect on long-term cardiovascular risk. Independent of its effect on blood pressure, telmisartan displays favourable effects on insulin resistance, lipid levels, left ventricular hypertrophy and renal function. Precautions General Telmisartan should not be given to patients with cholestasis, SA Pharmaceutical Journal – August 2010 SAPJAug10pp46-51.indd 51 Major adverse effects Telmisartan has a tolerability profile similar to that of placebo. Most commonly reported side effects include headache and dizziness. The excellent clinical tolerability of telmisartan is not affected by the association with the low-dose thiazide. Drug interactions Concomitant administration with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicines that may increase potassium levels is not recommended. Co-administration with lithium is not recommended. Telmisartan may increase serum digoxin concentrations. Cost: SEP (Incl VAT) Pritor® 40(80 mg) tablets: R125.40/28 Co-Pritor® 40(80)/12.5 mg tablets: R125.40/28 Manufacturer: Boehringer Ingelheim Patient information Tablets may be taken with food or on an empty stomach. Adequate contraceptive measures are advised for women of childbearing age. Conclusion Telmisartan is approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents, including a fixed-dose combination with hydrochlorothiazide. The long elimination half-life of telmisartan ensures the drug provides effective reductions in blood pressure across the entire 24-hour dosage interval. Extensive evidence from clinical trials indicates that telmisartan, either as monotherapy or in combination with other antihypertensive agents, provides long-term antihypertensive efficacy.r 51 8/5/2010 10:13:03 AM